Isis Pharmaceuticals, Inc. Form 10K - page 91

F-3
ISISPHARMACEUTICALS, INC.
CONSOLIDATEDBALANCESHEETS
(In thousands, except sharedata)
December 31,
2013 2012
ASSETS
Current assets:
Cash and cash equivalents ......................................................................................................... $ 159,973 $ 124,482
Short-term investments .............................................................................................................. 496,788 249,964
Contracts receivable ................................................................................................................... 11,102 522
Inventories ................................................................................................................................. 8,033 6,121
Investment inRegulus Therapeutics Inc. ................................................................................... 52,096 33,622
Other current assets .................................................................................................................... 7,518 8,727
Total current assets ................................................................................................................ 735,510 423,438
Property, plant and equipment, net ................................................................................................ 86,198 91,084
Licenses, net ................................................................................................................................... 4,572 6,579
Patents, net ..................................................................................................................................... 15,517 18,646
Deposits and other assets ............................................................................................................... 5,359 5,939
Total assets ......................................................................................................................... $ 847,156 $ 545,686
LIABILITIESANDSTOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable ....................................................................................................................... $ 11,009 $ 10,239
Accrued compensation ............................................................................................................... 12,168 7,878
Accrued liabilities ...................................................................................................................... 22,092 15,401
Current portionof long-termobligations ................................................................................... 4,408 4,879
Current portionof deferred contract revenue ............................................................................. 48,135 35,925
Total current liabilities ........................................................................................................... 97,812 74,322
Long-termdeferred contract revenue ............................................................................................. 142,790 66,656
234 percent convertible senior notes .............................................................................................. 150,334 143,990
Long-termobligations, less current portion ................................................................................... 6,542 7,402
Long-term financing liability for leased facility ............................................................................ 71,288 70,550
Total liabilities ................................................................................................................... 468,766 362,920
Stockholders’ equity:
Common stock, $0.001par value; 200,000,000 shares authorized, 116,471,371 and
101,481,134 shares issued and outstanding atDecember 31, 2013 and 2012, respectively ... 116 102
Additional paid-in capital .......................................................................................................... 1,324,804 1,077,150
Accumulatedother comprehensive income ............................................................................... 21,080 12,480
Accumulateddeficit ................................................................................................................... (967,610) (906,966)
Total stockholders’ equity ...................................................................................................... 378,390 182,766
Total liabilities and stockholders’ equity ........................................................................... $ 847,156 $ 545,686
See accompanyingnotes.